Overview

This trial is active, not recruiting.

Condition hemangioblastoma (hb) of the central nervous system (cns)
Treatment evaluation of anxiety with psychosocial scales
Sponsor Assistance Publique Hopitaux De Marseille
Start date May 2014
End date September 2016
Trial size 42 participants
Trial identifier NCT02120040, 2014-01

Summary

Von Hippel-Lindau (VHL) disease is a severe autosomal dominant genetic disorder (with almost complete penetrance) that predisposes to many tumors including some associated with a poorer outcome. Clear cell renal cell carcinoma (CCRCC) is the leading cause of mortality.

The diagnosis of VHL disease may be challenging because tumors have an asynchronous and multi-organ development and there is often no apparent hereditary context. As it is admitted that VHL disease is underdiagnosed, some countries have decided to recall patients presenting one of the potentially VHL disease-associated tumors to screen them for VHL mutation. Screening is currently recommended in guidelines but many patients may have not been previously screened.

Hemangioblastoma (HB) of the Central nervous system (CNS) is one of the typical VHL tumors and up to 20% of patients with HB show VHL mutation. VHL diagnosis in this population enables the diagnosis of other tumor types at an early stage of development since HB is chronologically the second tumor occurring during the VHL disease history.

But it raises critical problems and questions: difficult announcement of a potentially severe disease and psychosocial dimension related to inheritance of the disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Arm
(Other)
evaluation of anxiety with psychosocial scales

Primary Outcomes

Measure
evaluate the impact on anxiety of VHL mutation screening of patients operated for HB
time frame: two years

Secondary Outcomes

Measure
assessment of the mood
time frame: two years

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - age >=18; - Surgery for a CNS HB in the department of Neurosurgery of la Timone university hospital since 1999 ; - Absence of prior screening for VHL Exclusion Criteria: - minor, - incorrect French language

Additional Information

Principal investigator Philippe Metellus, MD
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille.